Pharmesis International Ltd (BFK) - Financial and Strategic SWOT Analysis Review

November 2021 | 39 pages | ID: P0D86A7AC96EN
GlobalData

Abstracts

Pharmesis International Ltd (BFK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Pharmesis International Ltd (Pharmesis) focuses on the research, development production, and commercialization of pharmaceutical products (Western medicine) and traditional Chinese medicines (TCM). It provides formulated products for the treatment of illnesses related to the liver and gall bladder. The company offers TCM formulated products through Longlife brand and Western medicine products through Kinna brand. Pharmesis also offers health supplements. The company has production facilities in the cities of Guilin, and Chengdu in the Sichuan Province. It has collaborations with research institutes in China to identify and develop new drugs. The company sells its products in China through an established sales and marketing network. Pharmesis is headquartered in Chengdu, Sichuan, China.

Pharmesis International Ltd Key Recent Developments

Aug 13,2021: Pharmesis International Announces Unaudited Condensed Interim Financial Statements for the 6 Months Ended 30 June 2021
Apr 28,2021: Pharmesis International announces Annual General Meeting
Apr 12,2021: Pharmesis International Announces Notice of Annual General Meeting to be held on 28 April 2021
Apr 01,2020: Pharmesis International: Resumption of operations at Gulin production facility
Feb 21,2020: Pharmesis International: Resumption of operations at our Chengdu production facility

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Pharmesis International Ltd - Key Facts
Pharmesis International Ltd - Key Employees
Pharmesis International Ltd - Key Employee Biographies
Pharmesis International Ltd - Major Products and Services
Pharmesis International Ltd - History
Pharmesis International Ltd - Company Statement
Pharmesis International Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Pharmesis International Ltd - Business Description
Business Segment: Distribution
Overview
Performance
Business Segment: TCM Formulated Drugs
Overview
Performance
Business Segment: Western drugs segment
Overview
Performance
R&D Overview
Pharmesis International Ltd - SWOT Analysis
SWOT Analysis - Overview
Pharmesis International Ltd - Strengths
Pharmesis International Ltd - Weaknesses
Pharmesis International Ltd - Opportunities
Pharmesis International Ltd - Threats
Pharmesis International Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Aug 13, 2021: Pharmesis International Announces Unaudited Condensed Interim Financial Statements for the 6 Months Ended 30 June 2021
Apr 28, 2021: Pharmesis International announces Annual General Meeting
Apr 12, 2021: Pharmesis International Announces Notice of Annual General Meeting to be held on 28 April 2021
Apr 01, 2020: Pharmesis International: Resumption of operations at Gulin production facility
Feb 21, 2020: Pharmesis International: Resumption of operations at our Chengdu production facility
Feb 06, 2020: Pharmesis International: Temporary closure of our production facilities

SECTION 5 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Pharmesis International Ltd, Key Facts
Pharmesis International Ltd, Key Employees
Pharmesis International Ltd, Key Employee Biographies
Pharmesis International Ltd, Major Products and Services
Pharmesis International Ltd, History
Pharmesis International Ltd, Other Locations
Pharmesis International Ltd, Subsidiaries
Pharmesis International Ltd, Key Competitors
Pharmesis International Ltd, Ratios based on current share price
Pharmesis International Ltd, Annual Ratios
Pharmesis International Ltd, Annual Ratios (Cont...1)
Pharmesis International Ltd, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Pharmesis International Ltd, Performance Chart (2016 - 2020)
Pharmesis International Ltd, Ratio Charts